Use of dabigatran in patients with non-valvular atrial fibrillation: answers to frequently asked questions

Vitamin K antagonists (VKA) were maintaining their position as the gold standard theraphy for stroke prevention in patients with non-valvular atrial fibrillation (AF) for years. As an alternative to VKA, the developed new-generation anticoagulant agents began to enter our daily practice more often. Nonetheless, with the increasing use of these agents, both patients and physicians are faced with different questions and clinical scenarios. This article is intended to respond to frequently asked questions related to a new generation anticoagulant agent: Dabigatran.